Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PDE6D | O43924 | 1/20 | 0.42 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.42 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16818500 | 0.79 | TDP1 (0.46) | ALDH1A1KDM4ETDP1POLBHTT | |
| SCHEMBL30883111 | 0.77 | SRC (0.39) | KMT2AMEN1LMNACYP2C9CYP2C19 | |
| SCHEMBL16818890 | 0.76 | ALDH1A1 (0.42) | ALDH1A1KDM4ETDP1POLBHTT | |
| SCHEMBL16818470 | 0.76 | TDP1 (0.43) | ALDH1A1KDM4ETDP1POLBHTT | |
| SCHEMBL16818583 | 0.76 | TDP1 (0.46) | ALDH1A1KDM4ETDP1POLBHTT | |
| SCHEMBL4802191 | 0.75 | CCR2 (0.59) | BRD4ALDH1A1KDM4EPOLBHTT | |
| SCHEMBL31402270 | 0.75 | CCR2 (0.59) | BRD4ALDH1A1KDM4EPOLBHTT | |
| SCHEMBL9941197 | 0.75 | BACE1 (0.42) | KDM4EHTTKMT2A | |
| SCHEMBL16818561 | 0.73 | BRD4 (0.54) | BRD4ALDH1A1KDM4ETDP1POLB | |
| SCHEMBL7213488 | 0.73 | PPARG (0.48) | ALDH1A1KDM4EHTTLMNAALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091484-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091484-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-10442803-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-10442803-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180002334-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2018-01-04 | — | — | US | disclosed |
| US-20180002334-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2018-01-04 | — | — | US | disclosed |
| US-9777003-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777003-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777003-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160168148-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-20160168148-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-20160168148-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-9309246-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309246-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309246-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2015095492-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095492-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175604-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175604-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175604-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002334-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | BRD4 5/4885ALDH1A1 4703/4885KDM4E 1807/4885 |
| US-10442803-B2 | Tricyclic heterocycles as bet protein inhibitors | BRD1, BRD3, BRD2 | BRD4 5/4885ALDH1A1 4703/4885KDM4E 1807/4885 |
| US-20160168148-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | BRD4 5/4885ALDH1A1 4703/4885KDM4E 1807/4885 |
| US-11091484-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | BRD4 5/4885ALDH1A1 4703/4885KDM4E 1807/4885 |
| US-20150175604-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | BRD4 5/4885ALDH1A1 4703/4885KDM4E 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.